Physician profile
Sandra S Bell
NPI 1508873084
$5,916.44
in general payments reported to CMS, 2019-2025
32 companies · $1,451 in 2025
The $1,451 reported for 2025 was more than what 92% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $564 · 2022: $125 · 2023: $1,448 · 2024: $2,329 · 2025: $1,451.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,228.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,227.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $688.62 | 2021-2022 | |
| Astrazeneca Pharmaceuticals LP | $477.52 | 2023-2025 | Lokelma, Calquence, Lynparza |
| Janssen Biotech, INC. | $353.78 | 2023-2024 | Darzalex, Tecvayli, Erleada |
| Daiichi Sankyo INC. | $338.51 | 2024-2025 | Injectafer, Vanflyta |
| E.R. Squibb & Sons, L.L.C. | $274.41 | 2023-2025 | Opdivo, Breyanzi, Reblozyl |
| Pharmacosmos Therapeutics INC. | $272.92 | 2023-2025 | Cosela, Monoferric |
| Jazz Pharmaceuticals INC. | $259.62 | 2024-2025 | |
| Regeneron Healthcare Solutions, INC. | $198.92 | 2025 | Libtayo |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $194.16 | 2023 | |
| Pfizer INC. | $184.13 | 2024-2025 | |
| Abbott Laboratories | $158.01 | 2024 | Freestyle Libre 3 |
| Celltrion USA INC. | $134.72 | 2024 | Zymfentra |
| Legend Biotech USA INC. | $130.80 | 2024 | |
| Beigene USA, INC. | $125.00 | 2024 | Brukinsa |
| Novo Nordisk INC | $124.99 | 2025 | Wegovy |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mylan Specialty L.P. | $124.99 | 2024 | Yupelri |
| Phathom Pharmaceuticals, INC. | $124.99 | 2024 | Voquezna |
| Idorsia Pharmaceuticals US INC | $124.99 | 2023 | Quviviq |
| Amgen INC. | $124.99 | 2023 | |
| Mannkind Corporation | $124.99 | 2023 | Afrezza |
| Aveo Pharmaceuticals, INC. | $124.99 | 2024 | |
| Sanofi-Aventis U.S. LLC | $124.99 | 2023 | |
| Glaxosmithkline, LLC. | $124.99 | 2025 | Ojjaara |
| Alnylam Pharmaceuticals INC. | $124.99 | 2024 | Givlaari |
| Myriad Genetic Laboratories, INC. | $124.99 | 2025 | Myrisk |
| Exelixis INC. | $124.99 | 2024 | Cabometyx |
| Syndax Pharmaceuticals, INC. | $121.27 | 2025 | Revuforj |
| Grifols USA, LLC | $120.18 | 2024 | Prolastin-C Liquid |
| Pharmaessentia USA Corporation | $119.43 | 2023 | Besremi |
| Neurelis, INC. | $117.44 | 2024 | Valtoco |
| Insulet Corporation | $104.72 | 2024 | Omnipod |
| Sun Pharmaceutical Industries INC. | $42.40 | 2023 | Odomzo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sandra Bell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.